ESC 365 - Summary and conclusion - Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management.

Open Access

Summary and conclusion - Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management.

Session: Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management

Topic: Heart failure, other

Speaker: Professor M. Boehm (Homburg, DE)

Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Michael Boehm

Saarland University Hospital, Homburg (Germany)

93 presentations

8 followers

4 more presentations in this session

Introduction - Enabling and renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management.

Speaker: Professor M. Boehm (Homburg, DE)

Renin-angiotensin-aldosterone system inhibitor therapy benefit and challenges in cardio-renal patients.

Speaker: Professor M. Weir (Baltimore, US)

Changing the treatment paradigm of hyperkalaemia management to enable and optimise renin-angiotensin-aldosterone system inhibitor therapy.

Speaker: Professor S. Anker (Berlin, DE)

Panel discussion - Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management.

Speaker: Professor M. Boehm (Homburg, DE)

Access the full session

Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management

Speakers: Professor M. Boehm, Professor M. Boehm, Professor M. Weir, Professor S. Anker, Professor M. Boehm

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources